Speedel CEO Alice Huxley: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Exec discusses Speedel’s other mid-stage pipeline candidates, the firm’s relationship with Novartis and business development going forward.
You may also be interested in...
Novartis Plans To Buy Back Speedel For $880 Million
Tekturna collaboration partner buys majority stake in company it once spun-out, plans tender offer for the rest.
Novartis Plans To Buy Back Speedel For $880 Million
Tekturna collaboration partner buys majority stake in company it once spun-out, plans tender offer for the rest.
Speedel CEO Alice Huxley: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Exec discusses Novartis’ hypertension treatment, Tekturna, which Speedel developed, as well as the benefits of other renin inhibitors in the Swiss biotech’s pipeline.